Abstract: Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Abstract: The present invention pertains to compounds effective at modulating (inhibiting or enhancing) RNA interference in a cell or organism. Featured compounds are set forth and exemplified herein. Therapeutic methods and pharmaceutical compositions featuring the compounds are also provided. The invention further pertains to knock-out or knock-down cells and organisms including the compounds, and methods of analysis of gene expression profiles and proteomes.

Abstract: The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino acid chelates can also be present, such as iron amino acid chelate, zinc amino acid chelate, copper amino acid chelate, manganese amino acid chelate, chromium amino acid chelate, and mixtures of second amino acid chelates.

Abstract: The present invention is directed to a compound of formula I, 1

Abstract: The present invention provides a safe therapeutic agent with negligible adverse effects, which activates eNOS so that it optimally functions, and thereby treats or prevents diseases or pathological conditions caused by a condition where the expression product of eNOS gene does not exhibit its proper function.

Abstract: The invention is concerned with a method and a composition for treating or preventing catabolism or of stimulating anabolism in a mammal undergoing metabolic stress. The method comprises administering to the mammal a composition containing methyl donors selected from the group consisting of L-serine, methionine, choline, phosphatidyl choline, betaine, dimethylglycine, sarcosine, methylated folates, S-adenosyl methionine, thymidine triphosphate, adenosine triphosphate and optionally methyl acceptors selected from the group consisting of L-glycine, ethanolamine, phosphatidyl ethanolamine, folate, ribose, wherein the total molar amount of methyl donors delivered by the method exceeds the total molar amount of methyl acceptors delivered by the method by at least 0.18 mmol per kg of body weight per day.

Abstract: A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of a combination of CPT-11, 5-fluorouracil and folinic acid, according to specific infusional treatment schedules which show therapeutic synergy in the treatment of cancer.

Abstract: The invention relates to a composition that contains the most potent combination of nutrients proven to assist in the treatment and prevention of cardiovascular disease, stroke, Alzheimer's disease and neurological degeneration by lowering elevated homocysteine levels. The present invention involves a composition for oral ingestion that contains essential amounts of Vitamin B6(Pyroxidine HCL and Pyridoxal 5-Phosphate), Folic Acid(folacin), Vitamin B12(Methylcobalamin), Zinc(Zinc L-monomethionine), N-acetyl Cysteine, and Inositol, as well as other ingredients and healthy filler ingredients.

Abstract: Methods and compositions are provided for the effective treatment of macular degeneration. The methods relate to administering a treatment including an effective amount of a combination of polyvinyl pyrollidone, procaine and thiamine to a mammalian host.

Abstract: The present invention provides methods of treating proliferative disease in a patient (e.g., a mammal such as a human) in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) an anti-platelet or anti-clotting agent and (2) an anti-neoplastic agent and/or radiation therapy. A second method of treatment comprises administering Plavix, also known as clopidogrel, or SR 25909 to a patient in need of such treatment. An additional method comprises administering an anti-platelet or anti-clotting agent to an individual at risk for developing proliferative disease. The methods of the present invention are particularly useful for the treatment or prevention of various cancers, especially epithelial cancers, e.g., prostate cancer, lung cancer, breast cancer, colorectal cancer, and pancreatic cancer.

Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.

Abstract: The present invention relates to new dihydropteridinones of general formula (I) 1

Abstract: The present invention provides a compliance system that contains at least one dispenser including at least one individual dose of an anti-folate therapeutic and at least one individual dose of a folic acid analog, each individual dose of anti-folate therapeutic and folic acid analog positioned in one or more individual compartments. Such a dispenser can have, for example, suitable indicia marked in association with each individual compartment, thereby identifying each compartment with the day or time when the enclosed anti-folate therapeutic or folic acid analog should be administered.

Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.

Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.

Abstract: A method of treating disorders marked by a loss of pigmentation, comprising the step of administering vitamin B12, copper, folic acid, and vitamin C to a patient suffering from a loss of pigmentation. Additionally, an effective amount of both pantothenic acid and zinc may be administered to said patient. Cutaneous repigmentation can be accelerated by the optional addition of exposure to sunlight or ultraviolet light.

Abstract: Reagents that block the extracellular activation of &bgr;-catenin are used to induce quiescence in normal stem cells, in order to reduce the killing of stem cells by anti-proliferative agents.

Abstract: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.

Abstract: The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects.

Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Abstract: Described is a composition for the prevention and treatment of symptoms associated with ethyl alcohol consumption. The composition comprises silymarin, salicin, at least one B vitamin, magnesium, molybdenum and manganese. Treatment of symptoms associated with the consumption of ethyl alcohol involves ingesting the described composition prior to, during, or after the consumption of the alcohol.

Abstract: Described are vitamin and mineral formulations comprising folic acid compound in amounts to promote healthy collagen, and optionally other vitamins and minerals such as vitamin B6, vitamin B12, calcium, magnesium, boron, as well as methods of administering such formulations to promote healthy collagen, to treat or prevent collagen-related conditions, and to facilitate tissue healing.

Abstract: Compounds according to the formula A-Z-W as herein described, wherein A is selected from the groups consisting of: A′-(CH2)n—, A′-(CH2)nSO2—, and A′-(CH2)nCO—, where n is 0 to 4; and A═ is selected from

Abstract: The invention provides certain thiazolopyrimidine compounds of formula (1) or a pharmaceutically acceptable salt or solvate thereof: in which: A is a group of formula (a) or (b): processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The two carbohydrate mixture of this invention utilizes a source of fructose in combination with at least one readily digestible glucose polymer source. The addition of the fructose significantly decreases the glycemic response when compared to the digestible glucose polymer alone. Additional components may be added to the simple two component carbohydrate mixture to form a carbohydrate system suitable for incorporation into an enteral nutritional. This carbohydrate system optionally incorporates nonabsorbent carbohydrates, dietary fiber and indigestible oligosaccharides. The present invention is also directed to an enteral nutritional which incorporates the two component carbohydrate mixture and less than 37% of calories from fat. Additionally, the invention is directed to a method of delivering nutrients to a person with diabetes by feeding the enteral nutritional.

Abstract: Compounds of formula (I) 1

Abstract: Methods are provided for enhancing the death of a neaplastic cell comprising the administration of a therapeutically effective concentration of a 14-3-3 antagonist and at least one antineoplastic therapeutic agent. The methods of the invention find use in improving the clinical outcome of a mammal having a neoplastic disorder and comprises administration to a mammal in need thereof at least one antineoplastic therapeutic agent in combination with a 14-3-3 antagonist. Further provided are pharmaceutical compositions having a therapeutically effective amount of a 14-3-3 antagonist and an antineoplastic therapeutic agent. Also provided are methods for identifying agents that selectively inhibit an interaction between a 14-3-3 polypeptide and a 14-3-3 ligand.

Abstract: Antitumor combinations comprising a taxane and at least one epidophllotoxin for treating neoplastic diseases are described.

Abstract: The present invention includes methods and compositions based on the discovery that T-lymphocytes from human AAA tissue have reactivity to the structural proteins in collagen.

Abstract: Antitumor combinations comprising a taxane and at least one antibiotic for treating neoplastic diseases are described.

Abstract: Antitumor combinations comprising a taxane and at least one antimetabolite for treating neoplastic diseases are described.

Abstract: Disclosed are dihydropteridinones of the formula (I): 1

Abstract: A vitamin and mineral supplement regimen for dialysis patients. The regimen comprises first and second formulations. The first formulation contains selenium, and no zinc, and is administered on days of dialysis. The second formulation contains zinc, and no selenium, and is administered on days between dialysis. In addition, the second formulation contains more vitamin C and folic acid than the first formulation.

Abstract: Piperidine derivatives of formula (I) and pharmaceutically derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.

Abstract: The present invention provides methods for treating a patient with an autoimmune disease by administering an inhibitor of adenosine deaminase (ADA) such as pentostatin and its analogs and derivatives.

Abstract: The invention is a composition and method for treating osteoporosis, bone loss and/or periodontal demineralization involving the oral administration of a formulation containing vanadium and ipriflavone which support an increase in bone mass, a homocysteine inhibitor/reducer to inhibit the counteracting effects of homocysteine on bone rebuilding, and an absorbable calcium salt to provide a ready source of material for bone rebuilding.

Abstract: Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Abstract: The present invention relates to a compound to selectively kill or protect a target cell in a patient with reduced systemic toxicity, which comprises a compound of the formula: W-Z-X wherein, X is a toxic agent or protective agent; W is a biologically active molecule which is adapted to selectively bind the target cell directly or indirectly; and Z is a breakable linker which covalently links W and X together, wherein the linked W remains bioavailable and bioactive, whereby the breakable linker releases the toxic agent or protective agent into the cell.

Abstract: This invention relates to novel dosage formulations for nutritional compositions comprising fatty acids derived from both plant and animal sources and methods for minimizing unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty in swallowing or ingesting nutritional agents. The nutritional compositions are intended for use by pregnant or lactating women.

Abstract: Pteridine compounds of formula (I) in which R1, R2, R3 and R4 are as specified in the claims, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases such as psoriasis, rheumatoid arthritis, diseases in which angiogenesis is assocated with raised CXCR2 chemokine levels (diabetic retinopathy) and COPD. The compounds are ligands for chemokine receptors and medical indications mentioned in the description include: diseases of the respiratory tract (COPDD, asthma, bronchitis, rhinitis, fibroid lung, pneumonia, etc.), diseases of the bones and joints (arthritis, etc.), skin-diseases (psoriasis, etc), diseases of the gastrointestinal tract, diseases in other tissues and systemic disease (multipe sclerosis, atherosclerosis, AIDS, type 1 diabetes, leprosy, sepsis, etc.), allograft rejection, cancers, cystic fibrosis, stroke, burn wounds, skin ulcers, reproductive disease and more.

Abstract: Compounds of formula (I) 1

Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.

Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.

Abstract: This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.

Abstract: Combinations comprising a) an inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor and b) an inhibitor of angiotensin converting enzyme (ACE) are useful for treating hypertension.

Abstract: This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.

Abstract: The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of N&dgr;-acyl derivatives of N&agr;(4-amino-4-deoxypteroyl)-L-omithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability than corresponding acidic N&dgr;-acyl derivatives of N&dgr;-acyl derivatives of N&agr;(4-amino-4-deoxypteroyl)-L-ornithine compounds.

Abstract: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies for treatment or prevention of cancer.

Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.